Thyrocare Technologies Toekomstige groei

Future criteriumcontroles 5/6

Thyrocare Technologies zal naar verwachting groeien in winst en omzet met respectievelijk 26.9% en 16.3% per jaar. De winst per aandeel zal naar verwachting groeien met 27.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 25.3% zijn.

Belangrijke informatie

26.9%

Groei van de winst

27.2%

Groei van de winst per aandeel

Healthcare winstgroei	27.6%
Inkomstengroei	16.3%
Toekomstig rendement op eigen vermogen	25.3%
Dekking van analisten	Low
Laatst bijgewerkt	24 Oct 2024

Recente toekomstige groei-updates

Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 26

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 04

Recent updates

Statutory Profit Doesn't Reflect How Good Thyrocare Technologies' (NSE:THYROCARE) Earnings Are

Oct 31

Thyrocare Technologies Limited (NSE:THYROCARE) Looks Just Right With A 26% Price Jump

Aug 01

Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 26

A Look At The Fair Value Of Thyrocare Technologies Limited (NSE:THYROCARE)

Jun 12

Getting In Cheap On Thyrocare Technologies Limited (NSE:THYROCARE) Might Be Difficult

Feb 29

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 04

Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt Responsibly

Dec 08

Why Thyrocare Technologies' (NSE:THYROCARE) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 08

Thyrocare Technologies (NSE:THYROCARE) Knows How To Allocate Capital Effectively

Mar 23

Thyrocare Technologies Limited (NSE:THYROCARE) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Mar 02

Investors In Thyrocare Technologies Limited (NSE:THYROCARE) Should Consider This, First

Feb 01

Investors Who Bought Thyrocare Technologies (NSE:THYROCARE) Shares A Year Ago Are Now Up 81%

Jan 12

The Chairman & MD of Thyrocare Technologies Limited (NSE:THYROCARE), Velumani Arokiaswamy, Just Bought A Few More Shares

Dec 24

Under The Bonnet, Thyrocare Technologies' (NSE:THYROCARE) Returns Look Impressive

Dec 17

Thyrocare Technologies Limited's (NSE:THYROCARE) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Nov 30

Analyst Forecasts For Thyrocare Technologies Limited (NSE:THYROCARE) Are Surging Higher

Nov 02

Earnings Update: Thyrocare Technologies Limited (NSE:THYROCARE) Just Reported And Analysts Are Boosting Their Estimates

Nov 01

Winst- en omzetgroeiprognoses

NSEI:THYROCARE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (INR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	9,319	1,647	2,087	2,074	2
3/31/2026	8,062	1,319	1,737	1,733	2
3/31/2025	6,828	998	1,595	1,559	2
9/30/2024	6,233	840	1,648	1,873	N/A
6/30/2024	5,939	776	N/A	N/A	N/A
3/31/2024	5,719	708	1,061	1,676	N/A
12/31/2023	5,535	655	N/A	N/A	N/A
9/30/2023	5,468	648	647	1,418	N/A
6/30/2023	5,338	599	N/A	N/A	N/A
3/31/2023	5,267	645	857	1,293	N/A
12/31/2022	5,214	731	N/A	N/A	N/A
9/30/2022	5,108	800	749	1,001	N/A
6/30/2022	5,520	1,423	N/A	N/A	N/A
3/31/2022	5,889	1,761	756	1,134	N/A
12/31/2021	6,051	1,924	N/A	N/A	N/A
9/30/2021	6,260	2,032	1,249	1,642	N/A
6/30/2021	6,030	1,685	N/A	N/A	N/A
3/31/2021	4,946	1,132	880	1,147	N/A
12/31/2020	4,503	741	N/A	N/A	N/A
9/30/2020	4,178	692	789	1,004	N/A
6/30/2020	3,797	612	N/A	N/A	N/A
3/31/2020	4,343	884	1,580	1,679	N/A
12/31/2019	4,384	1,063	N/A	N/A	N/A
9/30/2019	4,289	990	1,305	1,436	N/A
6/30/2019	4,165	892	N/A	N/A	N/A
3/31/2019	4,039	851	601	1,003	N/A
12/31/2018	3,946	939	N/A	N/A	N/A
9/30/2018	3,822	953	N/A	N/A	N/A
6/30/2018	3,663	947	N/A	N/A	N/A
3/31/2018	3,569	933	N/A	1,070	N/A
12/31/2017	3,493	1,117	N/A	N/A	N/A
9/30/2017	3,359	994	N/A	N/A	N/A
6/30/2017	3,258	759	N/A	N/A	N/A
3/31/2017	3,045	428	N/A	896	N/A
12/31/2016	2,843	659	N/A	N/A	N/A
9/30/2016	2,699	601	N/A	N/A	N/A
6/30/2016	2,535	564	N/A	N/A	N/A
3/31/2016	2,411	518	N/A	678	N/A
3/31/2015	1,835	452	N/A	345	N/A
3/31/2014	1,502	462	N/A	462	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei THYROCARE ( 26.9% per jaar) ligt boven de spaarquote ( 6.7% ).

Winst versus markt: De winst van THYROCARE ( 26.9% per jaar) zal naar verwachting sneller groeien dan de Indian markt ( 18.1% per jaar).

Hoge groeiwinsten: De winst van THYROCARE zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van THYROCARE ( 16.3% per jaar) zal naar verwachting sneller groeien dan de markt Indian ( 10.6% per jaar).

Hoge groei-inkomsten: De omzet van THYROCARE ( 16.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen THYROCARE zal naar verwachting over 3 jaar hoog zijn ( 25.3 %)

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2024/12/19 04:54
Aandelenkoers aan het einde van de dag	2024/12/19 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2024/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Thyrocare Technologies Limited wordt gevolgd door 12 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Alka Katiyar	Batlivala & Karani Securities India Pvt. Ltd.
Rahul Agarwal	CGS International
Kameswari V. S. Chavali	FirstCall Research

Thyrocare Technologies Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 9.1% to ₹903

Price target increased by 8.5% to ₹828

Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Price target increased by 7.3% to ₹695

Price target decreased by 7.0% to ₹730

Recent updates

MD, CEO & Chairman recently bought ₹1.1m worth of stock

Statutory Profit Doesn't Reflect How Good Thyrocare Technologies' (NSE:THYROCARE) Earnings Are

Price target increased by 9.1% to ₹903

Second quarter 2025 earnings released: EPS: ₹4.99 (vs ₹3.84 in 2Q 2024)

High number of new directors

Thyrocare Technologies Limited to Report Q2, 2025 Results on Oct 23, 2024

Now 23% overvalued after recent price rise

Price target increased by 8.5% to ₹828

Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million.

Thyrocare Technologies Limited Announces Cessation of Mr. Neetin Shivajirao Desai as Independent Director as Well as Member of the Respective Committee(s) of the Board

Now 20% overvalued after recent price rise

Thyrocare Technologies Limited Approves Dividend for the Financial Year 2023-24

Thyrocare Technologies Limited Announces Cessation of Gopalkrishna Shivaram Hegde as Independent Director and as Member / Chairman of the Respective Committee

Now 20% overvalued after recent price rise

Upcoming dividend of ₹18.00 per share

Thyrocare Technologies Limited, Annual General Meeting, Aug 23, 2024

Thyrocare Technologies Limited (NSE:THYROCARE) Looks Just Right With A 26% Price Jump

Investor sentiment improves as stock rises 20%

Thyrocare Technologies Limited (BSE:539871) acquired Diagnostic and pathological services business of Polo Labs Private Limited for INR 42.6 million.

Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Now 23% overvalued after recent price rise

First quarter 2025 earnings released: EPS: ₹4.52 (vs ₹3.26 in 1Q 2024)

Thyrocare Technologies Limited to Report Q1, 2025 Results on Jul 23, 2024

Now 23% overvalued after recent price rise

A Look At The Fair Value Of Thyrocare Technologies Limited (NSE:THYROCARE)

New major risk - Revenue and earnings growth

Thyrocare Technologies Limited Proposes Final Dividend for the Financial Year 2023-24

Thyrocare Technologies Limited to Report Q4, 2024 Results on May 14, 2024

Getting In Cheap On Thyrocare Technologies Limited (NSE:THYROCARE) Might Be Difficult

Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Think Health Diagnostic Private Limited.

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Third quarter 2024 earnings released: EPS: ₹2.78 (vs ₹1.89 in 3Q 2023)

Thyrocare Technologies Limited to Report Q3, 2024 Results on Feb 01, 2024

Price target increased by 7.3% to ₹695

Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt Responsibly

Why Thyrocare Technologies' (NSE:THYROCARE) Shaky Earnings Are Just The Beginning Of Its Problems

Second quarter 2024 earnings released: EPS: ₹3.84 (vs ₹3.80 in 2Q 2023)

Thyrocare Technologies Limited to Report Q2, 2024 Results on Oct 31, 2023

MD, CEO & Chairman recently bought ₹4.3m worth of stock

Thyrocare Technologies Limited Appoints Alok Kumar Jagnani as Chief Financial Officer

High number of new directors

Thyrocare Technologies Limited to Report Q1, 2024 Results on Aug 01, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited Accepts Resignation of Sachin Salvi as Chief Financial Officer

Price target decreased by 7.0% to ₹730

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q4, 2023 Results on May 23, 2023

Thyrocare Technologies Limited Announces Resignation of Vishwas Kulkarni as an Independent Director

Upcoming dividend of ₹18.00 per share at 3.1% yield

MD, CEO & Director recently bought ₹10m worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q3, 2023 Results on Feb 03, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited (BSE:539871) agreed to acquire 51% stake in Pulse Hitech Health Services (Ghatkopar) LLP for INR 25.5 million.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q2, 2023 Results on Nov 11, 2022

MD, CEO & Director recently bought ₹16m worth of stock

Thyrocare Technologies Limited Announces Payment of Interim Dividend for the Financial Year 2021-2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited, Annual General Meeting, Aug 03, 2022

Price target decreased to ₹1,073

Thyrocare Technologies Limited Joins Rahul Guha as Managing Director

Thyrocare Technologies Limited Declares Interim Dividend for the Financial Year 2021-22

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q4, 2022 Results on Apr 29, 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Thyrocare Technologies Limited Announces Appointment of Rahul Guha as Managing Director

Thyrocare Technologies Limited Appoints Sachin Salvi as Chief Financial Officer

First quarter 2022 earnings released: EPS ₹10.51 (vs ₹0.04 in 1Q 2021)